Journal article · 2023 · Open access

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo

Vita Golubovskaya, John Sienkiewicz, Jinying Sun, Shiming Zhang, Yanwei Huang, Hua Zhou, Hizkia Harto, Shirley Xu, Robert Berahovich, Lijun Wu

International Journal of Molecular Sciences, 24(17), 13364 · Published 29 August 2023 · DOI 10.3390/ijms241713364

Open PDFView at the publisherCite this paper

In brief

“CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo” is a 2023 journal article by Vita Golubovskaya and 9 co-authors, published in International Journal of Molecular Sciences. OpenAlex counts 68 citations as of 19 November 2026, which puts it in the top 7% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at International Journal of Molecular Sciences.

Citations
68
Most cited in
2026 (29)
Field-weighted impact
8.06
References
34
Authors
10

Abstract

Natural killer (NK) cells are cytotoxic lymphocytes that are critical for the innate immune system. Engineering NK cells with chimeric antigen receptors (CARs) allows CAR-NK cells to target tumor antigens more effectively. In this report, we present novel CAR mRNA-LNP (lipid nanoparticle) technology to effectively transfect NK cells expanded from primary PBMCs and to generate functional CAR-NK cells. CD19-CAR mRNA and BCMA-CAR mRNA were embedded into LNPs that resulted in 78% and 95% CAR expression in NK cells, respectively. BCMA-CAR-NK cells after transfection with CAR mRNA-LNPs killed multiple myeloma RPMI8226 and MM1S cells and secreted IFN-gamma and Granzyme B in a dose-dependent manner in vitro. In addition, CD19-CAR-NK cells generated with CAR mRNA-LNPs killed Daudi and Nalm-6 cells and secreted IFN-gamma and Granzyme B in a dose-dependent manner. Both BCMA-CAR-NK and CD19-CAR-NK cells showed significantly higher cytotoxicity, IFN-gamma, and Granzyme B secretion compared with normal NK cells. Moreover, CD19-CAR-NK cells significantly blocked Nalm-6 tumor growth in vivo. Thus, non-viral delivery of CAR mRNA-LNPs can be used to generate functional CAR-NK cells with high anti-tumor activity.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Golubovskaya, V., Sienkiewicz, J., Sun, J., Zhang, S., Huang, Y., Zhou, H., Harto, H., Xu, S., Berahovich, R., & Wu, L. (2023). CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo. International Journal of Molecular Sciences, 24(17), 13364. https://doi.org/10.3390/ijms241713364

MLA 9

Golubovskaya, Vita, et al. “CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.” International Journal of Molecular Sciences, vol. 24, no. 17, 2023, p. 13364. https://doi.org/10.3390/ijms241713364.

Chicago

Golubovskaya, Vita, John Sienkiewicz, Jinying Sun, Shiming Zhang, Yanwei Huang, Hua Zhou, Hizkia Harto, Shirley Xu, Robert Berahovich, and Lijun Wu. 2023. “CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.” International Journal of Molecular Sciences 24 (17): 13364. https://doi.org/10.3390/ijms241713364.

Harvard

Golubovskaya, V. et al. (2023) ‘CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo’, International Journal of Molecular Sciences, 24(17), p. 13364. doi:10.3390/ijms241713364.

IEEE

V. Golubovskaya et al., “CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo,” International Journal of Molecular Sciences, vol. 24, no. 17, p. 13364, 2023, doi: 10.3390/ijms241713364.

BibTeX

@article{golubovskaya2023cells,
  title     = {{CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo}},
  author    = {Golubovskaya, Vita and Sienkiewicz, John and Sun, Jinying and Zhang, Shiming and Huang, Yanwei and Zhou, Hua and Harto, Hizkia and Xu, Shirley and Berahovich, Robert and Wu, Lijun},
  journal   = {International Journal of Molecular Sciences},
  year      = {2023},
  volume    = {24},
  number    = {17},
  pages     = {13364},
  doi       = {10.3390/ijms241713364},
  url       = {https://doi.org/10.3390/ijms241713364}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202322
20242020
20251717
20262929

Its field-weighted citation impact is 8.06: it has been cited 8.06 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › CAR-T cell therapy research

  • CAR-NK cells
  • chimeric antigen receptor
  • lipid nanoparticle mRNA delivery
  • NK cell engineering
  • CD19 CAR
  • multiple myeloma
  • non-viral gene delivery
  • tumor cell killing

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Golubovskaya, V., Sienkiewicz, J., Sun, J., Zhang, S., Huang, Y., Zhou, H., Harto, H., Xu, S., Berahovich, R., & Wu, L. (2023). CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo. International Journal of Molecular Sciences, 24(17), 13364. https://doi.org/10.3390/ijms241713364

How many times has this paper been cited?

68 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at International Journal of Molecular Sciences: sign in and open the PDF from this page.

Who wrote this paper?

Vita Golubovskaya, John Sienkiewicz, Jinying Sun, Shiming Zhang, Yanwei Huang, Hua Zhou, Hizkia Harto, Shirley Xu, Robert Berahovich, Lijun Wu.

What is the DOI of this paper?

10.3390/ijms241713364, permanently at https://doi.org/10.3390/ijms241713364. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.